PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Two Versus Three Induction Cycles in Nasopharyngeal Carcinoma: Equal Survival, More Toxicity

induction chemotherapydocetaxelcisplatinnedaplatin5-fluorouracilTPFconcurrent chemoradiotherapynasopharyngeal carcinomalocally advancedpropensity score matchingretrospective cohorttoxicitynumber of cycles Oncology Pharmacy

Background Information

Two chemo cycles reduce toxicity in nasopharyngeal cancer.

Determining the optimal number of chemotherapy cycles could improve treatment tolerability in nasopharyngeal carcinoma. Two cycles of induction chemotherapy showed similar survival outcomes but lower toxicity compared to three cycles. This study suggests fewer induction chemotherapy cycles might minimize toxicity with no loss in efficacy, but it is limited by its retrospective design. Two chemo cycles may suffice for advanced nasopharyngeal carcinoma, reducing toxicity.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Xie R, Lin X, Li Q, Pan J, Xie K, Chen J, Zhang Y, Chen C, Zhan Y

Citation: Xie R, Lin X, Li Q, et al. Comparative efficacy and toxicity of two versus three induction chemotherapy cycles in locally advanced nasopharyngeal carcinoma: a propensity score matching analysis. BMC cancer. 2026;26(1). doi:10.1186/s12885-026-16655-2

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.